Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription 07.05.2018 1 AJR Am J Roentgenol 1 Am J Respir Cell Mol Biol 1 Ann Oncol 1 Ann Thorac Surg 3 Anticancer Res 1 BMC Cancer 1 Cancer Chemother Pharmacol 2 Clin Cancer Res 1 Clin Lung Cancer 2 Clin Nucl Med 1 Eur J Cardiothorac Surg 1 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 2 J Thorac Cardiovasc Surg 10 J Thorac Oncol 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJR Am J Roentgenol

1. HANSBERRY DR, White MD, D'Angelo M, Prabhu AV, et al
   Lung Cancer Screening Guidelines: How Readable Are Internet-Based Patient Education Resources?
   AJR Am J Roentgenol. 2018 Apr 30:W1-W5. doi: 10.2214/AJR.17.19042.
   PubMed     Text format     Abstract available
   
   

   
   Am J Respir Cell Mol Biol

2. KESHAMOUNI VG
   Excavation of FOSL1 in the Ruins of KRAS-Driven Lung Cancer.
   Am J Respir Cell Mol Biol. 2018;58:551-552.
   PubMed     Text format    
   
   

   
   Ann Oncol

3. BUTTERBAUGH ST, Patel R, Romond EH, Mathew A, et al
   Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.
   Ann Oncol. 2017 Sep 18. doi: 10.1093.
   PubMed     Text format    
   
   

   
   Ann Thorac Surg

4. JUDY GD, Kaidar-Person O, Deal A, Wang Y, et al
   The Persistent Problem of Local/Regional Failure Following Surgery for Early-Stage Lung Cancer.
   Ann Thorac Surg. 2018 Apr 30. pii: S0003-4975(18)30559.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

5. SHINOHARA S, Sugaya M, Onitsuka T, Machida K, et al
   Prognostic Impact of Postoperative C-reactive Protein for Non-small Cell Lung Cancer Following Lobectomy.
   Anticancer Res. 2018;38:3193-3198.
   PubMed     Text format     Abstract available
   
   
6. KINOSHITA F, Toyokawa G, Tagawa T, Matsubara T, et al
   Takotsubo Cardiomyopathy Developed After Two-stage Surgery for Double Primary Lung Cancer.
   Anticancer Res. 2018;38:2957-2960.
   PubMed     Text format     Abstract available
   
   
7. ALMQUIST D, Khanal N, Smith L, Ganti AK, et al
   Preoperative Pulmonary Function Tests (PFTs) and Outcomes from Resected Early Stage Non-small Cell Lung Cancer (NSCLC).
   Anticancer Res. 2018;38:2903-2907.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

8. QUAIFE SL, Vrinten C, Ruparel M, Janes SM, et al
   Smokers' interest in a lung cancer screening programme: a national survey in England.
   BMC Cancer. 2018;18:497.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Chemother Pharmacol

9. SMIT EF, Garon EB, Reck M, Cappuzzo F, et al
   Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2018 May 2. pii: 10.1007/s00280-018-3560.
   PubMed     Text format     Abstract available
   
   

   
   Clin Cancer Res

10. HIGGS BW, Morehouse C, Streicher KL, Brohawn P, et al
    Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small-Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.
    Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3451.
    PubMed     Text format     Abstract available
    
    
11. NAZ S, Sowers AL, Choudhuri R, Wissler MF, et al
    Abemaciclib, a Selective CDK4/6 Inhibitor Enhances the Radiosensitivity of Non-Small Cell Lung Cancer in vitro and in vivo.
    Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3575.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

12. VISSER S, de Mol M, Cheung K, van Toor JJ, et al
    Treatment Satisfaction of Patients With Advanced Non-Small-cell Lung Cancer Receiving Platinum-based Chemotherapy: Results From a Prospective Cohort Study (PERSONAL).
    Clin Lung Cancer. 2018 Mar 17. pii: S1525-7304(18)30045.
    PubMed     Text format     Abstract available
    
    

    
    Clin Nucl Med

13. PAN Y, Zhang Y
    Simultaneous Brain and Lung Histiocytic Sarcoma Revealed on 18F-FDG PET/CT.
    Clin Nucl Med. 2017 Nov 17. doi: 10.1097/RLU.0000000000001908.
    PubMed     Text format     Abstract available
    
    
14. MAGARIK MA, Walker RC, Gilbert J, Manning HC, et al
    Intracardiac Metastases Detected by 18F-FSPG PET/CT.
    Clin Nucl Med. 2017 Oct 26. doi: 10.1097/RLU.0000000000001883.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cardiothorac Surg

15. VERONESI G, Park B, Cerfolio R, Dylewski M, et al
    Robotic resection of Stage III lung cancer: an international retrospective study.
    Eur J Cardiothorac Surg. 2018 Apr 30. pii: 4990523. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

16. TZENG HT, Su CC, Chang CP, Lai WW, et al
    Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages towards tumor-suppressing phenotype.
    Int J Cancer. 2018 May 1. doi: 10.1002/ijc.31569.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

17. SHINTANI T, Matsuo Y, Iizuka Y, Mitsuyoshi T, et al
    A Retrospective Long-term Follow-up Study of Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer From a Single Institution: Incidence of Late Local Recurrence.
    Int J Radiat Oncol Biol Phys. 2018;100:1228-1236.
    PubMed     Text format     Abstract available
    
    
18. URBANIC JJ, McGarry RC, Daly ME, Palma DA, et al
    Locally Advanced Lung Cancer: Is It Time to Take Cardiac Protection Seriously in Radiation Planning?
    Int J Radiat Oncol Biol Phys. 2018;100:1091-1094.
    PubMed     Text format    
    
    

    
    J Clin Oncol

19. REINMUTH N, Reck M
    Breaking the Glass Ceiling of Overall Survival in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Apr 30:JCO2018782102. doi: 10.1200/JCO.2018.78.2102.
    PubMed     Text format    
    
    

    
    J Thorac Cardiovasc Surg

20. YENDAMURI S, Dhillon SS, Groman A, Dy G, et al
    Effect of the number of lymph nodes examined on the survival of patients with stage I non-small cell lung cancer who undergo sublobar resection.
    J Thorac Cardiovasc Surg. 2018 Apr 4. pii: S0022-5223(18)30895.
    PubMed     Text format     Abstract available
    
    
21. CAO J, Xu J, He Z, Yuan P, et al
    Prognostic impact of lymphadenectomy on outcomes of sublobar resection for stage IA non-small cell lung cancer </=2 cm.
    J Thorac Cardiovasc Surg. 2018 Apr 6. pii: S0022-5223(18)30905.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Oncol

22. HERMAN M, Warkentin MT, Shepshelovich D, Latifovic L, et al
    Heritable Germline Variation and Lung Cancer Susceptibility: One Size Does not Fit All.
    J Thorac Oncol. 2018;13:601-602.
    PubMed     Text format    
    
    
23. DRESLER C, Warren GW, Arenberg D, Yang P, et al
    "Teachable Moment" Interventions in Lung Cancer: Why Action Matters.
    J Thorac Oncol. 2018;13:603-605.
    PubMed     Text format    
    
    
24. MARTINEZ VILA C, Garcia Garcia Y, Carcereny Costa E
    Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e77-e79.
    PubMed     Text format    
    
    
25. HOYLE C, Dyer M
    Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2018;13:e83-e84.
    PubMed     Text format    
    
    
26. WU B
    Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2018;13:e84-e85.
    PubMed     Text format    
    
    
27. SAFIRI S, Ashrafi-Asgarabad A
    Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab: Methodological Issues.
    J Thorac Oncol. 2018;13:e85-e86.
    PubMed     Text format    
    
    
28. MUNARI E, Zamboni G, Lunardi G, Marchionni L, et al
    PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsies and whole sections.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30543.
    PubMed     Text format     Abstract available
    
    
29. LI Z, Shen L, Ding D, Huang J, et al
    Efficacy of Crizotinib Among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-small-cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30542.
    PubMed     Text format     Abstract available
    
    
30. VAN KEMPEN LC, Wang H, Aguirre ML, Spatz A, et al
    Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P794L mutated Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30548.
    PubMed     Text format    
    
    
31. DUDNIK E, Peled N, Nechushtan H, Wollner M, et al
    BRAF mutant lung cancer: PD-L1 expression, tumor mutational burden, microsatellite instability status and response to immune check-point inhibitors.
    J Thorac Oncol. 2018 Apr 30. pii: S1556-0864(18)30552.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

32. CIRCU M, Cardelli J, Barr MP, O'Byrne K, et al
    Correction: Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.
    PLoS One. 2018;13:e0197016.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: